Ovitrelle 250 micrograms/0.5 mL solution for injection in pre-filled syringe
Sponsors
Ferring Pharmaceuticals A/S, Universitair Ziekenhuis Gent, Santiago Dexeus Font Fundacio Privada, Rigshospitalet
Conditions
InfertilityInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycleSubfertilitydiminished ovarian reserve.infertility
Phase 3
A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the ovarian response after controlled ovarian stimulation with mixed protocols of follitropin delta (REKOVELLE) and highly purified human menopausal gonadotropin (MENOPUR) in women undergoing an assisted reproductive technology programme
Not yet recruitingCTIS2022-500308-23-00
Target: 115Updated: 2022-11-09
Eight weeks of low dose hCG priming in women with diminished ovarian reserve undergoing IVF/ICSI – a randomized controlled trial
RecruitingCTIS2025-521234-28-00
Start: 2025-09-10Target: 80Updated: 2025-06-03
Phase 4
A randomized comparison of one controlled ovarian stimulation with corifollitropin alfa (CFA) versus up to three modified natural cycles (MNC) in expected and established poor responders
RecruitingCTIS2023-509094-23-00
Start: 2022-07-15Target: 300Updated: 2025-04-28
The impact of the intensity of ovarian stimulation on embryo quality in predicted suboptimal responders. A randomized controlled trial.
Not yet recruitingCTIS2024-514322-23-00
Target: 110Updated: 2024-09-09